How life sciences companies can mitigate emerging risks
Life sciences companies are continuing to adopt patient ambassador programs as a popular tool to overcome barriers of entry to niche populations. With the industry moving towards a patient-centric approach to healthcare advocacy, these programs help put the patient back in the driver’s seat by having ambassadors educate and share their experiences with patients and family members of similar backgrounds. However, with the Office of the Inspector General’s (OIG) renewed focus on interactions with patients, the use of patient ambassador programs is receiving increased scrutiny with how information is being disseminated to the medical community and patient populations.
Listen to Baker Tilly’s informative, on-demand webinar where our team discussed the benefits and risks of patient ambassador programs. In addition to giving a background on the OIG’s recent scrutiny on patient interactions, we discussed how life sciences organizations can identify and mitigate these emerging risks followed with a wrap up of practical tips organizational leaders can use to build an effective and compliant patient ambassador program.